Please login to the form below

Not currently logged in
Email:
Password:

Aurobindo

This page shows the latest Aurobindo news and features for those working in and with pharma, biotech and healthcare.

Teva sells UK and Ireland assets to Intas Pharma for £603m

Teva sells UK and Ireland assets to Intas Pharma for £603m

In the weeks leading up to the sale, generic drugmaker Aurobindo and private equity firms Cinven and Apollo Global Management were reported as being in negotiations over the purchase.

Latest news

More from news
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    140. Generis. Aurobindo. Company acquisition. Generic products. 135. Maverick. Takeda. Option to acquire.

  • Pharma deals in July 2015 Pharma deals in July 2015

    In early 2014 Actavis sold most of its European generics business to Aurobindo and in March 2015 completed the acquisition of Allergan.

  • Pharma deals during January 2014 Pharma deals during January 2014

    Slimming the business down a little, Actavis sold some of its generic products in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands to Aurobindo for $41m.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Ramprasad Reddy to chair Aurobindo’s US business

    Ramprasad Reddy to chair Aurobindo’ s US business. Will also step down from position as full-time director. ... In addition, Aurobindo's board also approved that Ramprasad Reddy relinquish his executive responsibilities as full-time director of the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics